【一周新资讯--乳腺癌 315】2024 W3703

文章预览

11 阿替利珠单抗、帕妥珠单抗与高剂量曲妥珠单抗治疗CNS转移HER2阳性乳腺癌的II期研究 主要研究结果： • 共纳入19例脑转移HER2阳性乳腺癌   • 接受阿替利珠单抗1200mg IV Q3W、帕妥珠单抗起始840mg IV随后420mg IV Q3W与高剂量曲妥珠单抗6mg/kg IV QW 24周随后6mg/kg IV Q3W • 主要终点确认的颅内部分缓解CNS PR(RANO-BM)为10.5%，未达到预设的疗效阈值，早期终止 • 18/24周CBR=42.1/31.6%，减量或暂停36.8%，最常见任何级别AE为腹泻与乏力(各26.3%) 参考文献： Giordano A, Kumthekar PU, Jin Q, Binboga Kurt B, Ren S, Li T, Leone JP, Mittendorf EA, Pereslete AM, Sharp L, Davis R, DiLullo M, Tayob N, Mayer EL, Winer EP, Tolaney SM, Lin NU. A phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for central nervous system metastases in patients with HER2-positive breast cancer. Clin Cancer Res. 2024 Sep 3. doi: 10.1158/1078-0432.CCR-24-1161. Epub ahead of prin ………………………………